Division of Pharmacology and Therapy, Department of Anatomy Histology and Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.
Department of Health Science, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Med Sci Monit. 2024 Apr 21;30:e943863. doi: 10.12659/MSM.943863.
BACKGROUND Economic evaluation of the testing strategies to control transmission and monitor the severity of COVID-19 after the pandemic is essential. This study aimed to review the economic evaluation of COVID-19 tests and to construct a model with outcomes in terms of cost and test acceptability for surveillance in the post-pandemic period in low-income, middle-income, and high-income countries. MATERIAL AND METHODS We performed the systematic review following PRISMA guidelines through MEDLINE and EMBASE databases. We included the relevant studies that reported the economic evaluation of COVID-19 tests for surveillance. Also, we input current probability, sensitivity, and specificity for COVID-19 surveillance in the post-pandemic period. RESULTS A total of 104 articles met the eligibility criteria, and 8 articles were reviewed and assessed for quality. The specificity and sensitivity of COVID-19 screening tests were reported as 80% to 90% and 40% to 90%, respectively. The target population presented a mortality rate between 0.2% and 19.2% in the post-pandemic period. The implementation model of COVID-19 screening tests for surveillance with a cost mean for molecular and antigen tests was US$ 46.64 (min-max US $0.25-$105.39) and US $6.15 (min-max US $2-$10), respectively. CONCLUSIONS For the allocation budget for the COVID-19 surveillance test, it is essential to consider the incidence and mortality of the post-pandemic period in low-income, middle-income, and high-income countries. A robust method to evaluate outcomes is needed to prevent increasing COVID-19 incidents earlier.
在大流行后控制 COVID-19 的传播和监测严重程度的测试策略的经济评估至关重要。本研究旨在回顾 COVID-19 检测的经济评估,并构建一个在中低收入、中高收入国家的大流行后监测中以成本和检测可接受性为结果的模型。
我们按照 PRISMA 指南通过 MEDLINE 和 EMBASE 数据库进行了系统评价。我们纳入了报告 COVID-19 检测监测经济评估的相关研究。此外,我们输入了大流行后时期 COVID-19 监测的当前概率、敏感性和特异性。
共有 104 篇文章符合入选标准,其中 8 篇文章进行了综述和质量评估。COVID-19 筛查试验的特异性和敏感性分别报告为 80%至 90%和 40%至 90%。大流行后时期目标人群的死亡率在 0.2%至 19.2%之间。COVID-19 筛查试验监测的实施模型的平均成本为分子和抗原检测分别为 46.64 美元(最低-最高为 0.25 美元至 105.39 美元)和 6.15 美元(最低-最高为 2 美元至 10 美元)。
对于 COVID-19 监测检测的分配预算,必须考虑中低收入、中高收入和高收入国家大流行后的发病率和死亡率。需要一种强大的方法来评估结果,以防止更早地增加 COVID-19 事件。